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The complexity of vaccine manufacturing has raised the need to drive standardization and quality control
requirements as well as batch release of vaccines. The purpose of release testing is to ensure that efficacy and
safety of the vaccine product are maintained in all batches. Classical testing includes challenge experiments in
animals that provide proof of vaccine potency and identify subpotent vaccines. However, novel concepts such
as “consistency testing” question the continued need for in vivo experiments and propose to implement rigorous
QC for lot-to-lot consistency testing with other methods at an earlier stage.
In views of these developments and the recent changes in the animal legislation the Paul-Ehrlich-Institut (PEI)
as OMCL (official medicines control laboratory) has substituted challenge experiments for tetanus and
diphtheria by serological testing for immunogenicity. The development of a multiplex-assay using
electrochemiluminescence was favored because measurements performed with this technology remain linear
over broad concentration ranges and deliver robust and reliable results.
Ongoing developments at PEI further include in vitro methods for functional testing of DTaP bulk antigen using
cell-based assays based on eliciting antigen-specific B cell responses in human peripheral blood cells and
Raman spectroscopy-based approaches for identification of vaccines as a rapid, non-invasive technology.
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